Researchers found significant sex-based differences in ILD in patients with interdisciplinary indications for complete ...

Aspyre Clinical Test for Lung (Tissue) tests lung FFPE and blood samples for actionable ... Clinical sample and internal laboratory processing characteristics analyzed included biopsy type, pathology ...

Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022.

In summary, Zero-Stage Lung Cancer is highly treatable when caught early Veteran actress Sharmila Tagore recently shared a deeply personal revelation that she had battled cancer. The news took ...

Initial evaluation consists of a detailed history, physical exam and review of old and new images, as well as a chest CT scan with thin 1 mm slices through the lung nodules. Multiple models are ...

ARP Atlases. 2007;1:17-47. The total number of leukocytes recovered by lavage is determined by examination of a sample of the pooled fluid with a hemocytometer. The cell counts are most accurate ...

Apr. 22, 2025 — Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

"I thought I may have pulled a muscle, went to the VA and, in fact, had a collapsed lung," she said. The local VA coordinated her care immediately with Highland Hospital. Medical staff determined ...

Early diagnosis of lung cancer may improve the prognosis, but many people aren’t aware they have it until it spreads. Screening tests may help detect the disease. Blood tests are not yet ...

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...